Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?

Ann Rheum Dis. 2012 Mar;71(3):472-3. doi: 10.1136/annrheumdis-2011-200370. Epub 2011 Sep 8.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived / economics
  • Antirheumatic Agents / administration & dosage*
  • Antirheumatic Agents / economics
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / economics
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Retreatment
  • Rituximab
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Rituximab